clenoliximab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 422317915

| image =

| type = mab

| mab_type = mab

| source = xi/i

| target = CD4

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 182912-58-9

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 78EVW7GX37

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB06241

| chemical_formula =

| molecular_weight =

}}

Clenoliximab (INN{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77 | journal = WHO Drug Information | volume = 11 | issue = 2 | pages = 89 | year = 1997 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf| archive-url = https://web.archive.org/web/20040627024153/http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf| url-status = dead| archive-date = June 27, 2004}}) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.{{cite journal | vauthors = Hepburn TW, Totoritis MC, Davis CB | title = Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis | journal = Rheumatology | volume = 42 | issue = 1 | pages = 54–61 | date = January 2003 | pmid = 12509613 | doi = 10.1093/rheumatology/keg030 }}

The drug is a chimeric antibody from Macaca irus and Homo sapiens.